Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Armandi

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Journal of Hepatology|June 23, 2025
Impact of first and further decompensation in patients with compensated ACLD due to MASLDGrazia Pennisi, Gabriele Di Maria, Vincent Wai-Sun Wong, et al.
Gut|January 10, 2024
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver diseaseAngelo Armandi, Tiziana Sanavia, Ramy Younes, et al.
JAMA|March 21, 2024
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver DiseaseHuapeng Lin, Hye Won Lee, Terry Cheuk-Fung Yip, et al.
Journal of Hepatology|January 25, 2025
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver diseaseTerry Cheuk-Fung Yip, Hye Won Lee, Huapeng Lin, et al.
Hepatology (Baltimore, Md.)|December 26, 2025
Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver diseaseYangyue Zhang, Hye Won Lee, Huapeng Lin, et al.
Clinical and Molecular Hepatology|November 11, 2025
Histological severity and hepatic outcomes in patients with MASLD and discrepant FIB-4 and liver stiffness measurementJoseph Rabbat, Boyu Yang, Hye Won Lee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 9, 2025
Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLDYu Shi, Seung Up Kim, Terry Cheuk-Fung Yip, et al.
Gut|August 1, 2024
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver diseaseXiao-Dong Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 8, 2026
Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular RiskXiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, et al.
Gut|June 20, 2025
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Boyu Yang, Hye Won Lee, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Journal of Hepatology|June 23, 2025
Impact of first and further decompensation in patients with compensated ACLD due to MASLDGrazia Pennisi, Gabriele Di Maria, Vincent Wai-Sun Wong, et al.
Gut|January 10, 2024
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver diseaseAngelo Armandi, Tiziana Sanavia, Ramy Younes, et al.
JAMA|March 21, 2024
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver DiseaseHuapeng Lin, Hye Won Lee, Terry Cheuk-Fung Yip, et al.
Journal of Hepatology|January 25, 2025
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver diseaseTerry Cheuk-Fung Yip, Hye Won Lee, Huapeng Lin, et al.
Hepatology (Baltimore, Md.)|December 26, 2025
Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver diseaseYangyue Zhang, Hye Won Lee, Huapeng Lin, et al.
Clinical and Molecular Hepatology|November 11, 2025
Histological severity and hepatic outcomes in patients with MASLD and discrepant FIB-4 and liver stiffness measurementJoseph Rabbat, Boyu Yang, Hye Won Lee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 9, 2025
Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLDYu Shi, Seung Up Kim, Terry Cheuk-Fung Yip, et al.
Gut|August 1, 2024
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver diseaseXiao-Dong Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 8, 2026
Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular RiskXiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, et al.
Gut|June 20, 2025
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Boyu Yang, Hye Won Lee, et al.
Pageof 13